Bergen, Norway, 1 July 2025 -- Lifecare ASA (LIFE), a medtech company
developing next-generation Continuous Glucose Monitoring (CGM) technology for
diabetes management, today announces the completion of initial testing of
electronics developed for our Continuous Glucose Monitoring implant.
This initial testing of the electronics for use in our implant with wireless
communication includes electromagnetic compatibility (EMC) and Radio Frequency
(Rf). The first EMC tests of electronics were completed by ShortLink
Compliance AB and reported to Lifecare.
EMC testing checks whether the electronics used in our implant and read-out
unit will function correctly in the real world, where it will be surrounded by
things like mobile phones, Wi-Fi, and other wireless technologies. The results
from our first EMC tests confirm a stable technical foundation for the implant
system, validating the core system performance under standard EMC conditions,
supporting the next phase of refinement and final verification.
The results mark an important milestone in the company's CE-marking process
and broader regulatory strategy.
"We are pleased with the outcome of this testing round, which confirms that
our electronics perform according to expectations at this preclinical stage,"
said Joacim Holter, CEO of Lifecare ASA. "This is a planned and productive
step in our quality assurance process, and we are now moving forward with
optimizations to secure full regulatory compliance."
While final adjustments will be implemented to prepare for the final round of
compliance testing of electronics, Lifecare stays on track to start the
first-in-human clinical trials this year, as previously announced. Lifecare
anticipates completing the regulatory testing phase in time for CE-mark
submission in 2026 and commercial launch in 2027.
The testing was conducted by ShortLink Compliance AB, an independent certified
lab, using internationally recognized standards. The process was supported by
a special high-activity operating mode designed to push the system to its
limits and confirm reliability under demanding conditions. Lifecare
anticipates completing final verification activities within three months.
About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring ("CGM") systems to market.
Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor
technology is suitable for identifying and monitoring the occurrence of a wide
range of analytes and molecules in the human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42